Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis

The 2022 World Health Organization guidelines recommend use of two core anti-tuberculosis (TB) drugs, bedaquiline (BDQ) and clofazimine (CFZ), for treatment of drug-resistant (DR)-TB. However, several mutated Mycobacterium tuberculosis (MTB) genes, conferring BDQ and CFZ resistance, have been report...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jin, Liu, Yuanyuan, Wu, Tuoya, Li, Lu, Han, Shujing, Peng, Xiao, Shang, Yuanyuan, Guo, Yongli, Pang, Yu, Gao, Mengqiu, Lu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581187/
https://www.ncbi.nlm.nih.gov/pubmed/37646524
http://dx.doi.org/10.1128/spectrum.00090-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581187/
https://www.ncbi.nlm.nih.gov/pubmed/37646524
http://dx.doi.org/10.1128/spectrum.00090-23

Ejemplares similares